Ticker: OCGN

Ocugen, Inc. (NASDAQ: OCGN) has recently reported its financial results for the quarter ending June 30, 2025, reflecting both progress and challenges as the company focuses on developing gene therapies for retinal diseases. Positive Aspects: Collaborative arrangement revenue increased to $1.373 ...